 |
| Sep |
Worldwide license and co-development Agreement of Epirubicin Micelle (NC-6300) with KOWA company Ltd. |
| Jul |
Started phase Ⅱ clinical trial of Nanoplatin (NC-6004) in Taiwan&Singapore. |
 |
| Dec |
Collaborative research agreement with National Cancer Center to initiate a preclinical study of Epirubicin Micelle(NC-6300).
|
| Oct |
Option agreement of protein micelle for rhFVIIa with LFB Biotechnologies. |
| Aug |
Nippon Kayaku Co., Ltd. started phase I clinical trail(Breast Cancer) of Paclitaxel Micelle (NK105). |
 |
| May |
In-licensed "Cationic Polyamino Acids" from the University of Tokyo and TOUDAI TLO, Ltd. |
| Mar |
Started phase I clinical trial of DACH-platin Micelle (NC-4016) in EU. |
 |
| Dec |
IND Application of Nanoplatin® for Phase I/II study was approved in Taiwan |
| Sep |
License and co-development Agreement of Nanoplatin (NC-6004) with Orient Europharma Co., Ltd. |
| Apr |
Exclusive License Agreement signed with Toudai TLO, Ltd. on Incorporated Nucleic Acids into Micelles |
| Mar |
NanoCarrier got listed on the Tokyo Stock Exchanges Mothers |
 |
| Nov |
Nippon Kayaku Co., Ltd. started phase II clinical trail(gastric cancer) of Paclitaxel Micelle (NK105). |
| Feb |
In-licensed “A new block copolymer for preparation of pH-sensitive polymeric micelle and a production process thereof” from the University of Tokyo and TOUDAI TLO, Ltd. |
 |
| Aug |
In-licensed “Physical trapping type polymeric micelle drug preparation”, for the research and development of paclitaxel micelle (NK105) with Japan Science and Technology Agency. |
| Jul |
Obtained exclusive license of “Electrostatic bonding type macromolecular micelle drug carrier and drug carried thereon” from TOUDAI TLO, Ltd. |
| May |
Started phase I clinical trial of Nanoplatin® (NC-6004) in U.K. |
 |
| Jul |
Formed partnership with TOUDAI TLO, Ltd for “discovery and development of drugs with high usability for treatment of solid cancers”. |
| Mar |
Formed partnership with Debiopharm S.A. for DACH-Platin micelle (NC-4016). |
 |
| Aug |
Moved head office and lab to Tohdai Kashiwa Venture Plaza in Kashiwa, Chiba. |
| May |
Nippon Kayaku Co., Ltd., a licensed company in Japan, started phase I clinical trial of Paclitaxel Micelle (NK105). |
|
In-licensed “Coordinate complex of diaminocyclohexaneplatinum (II) with block copolymer containing poly (carboxylic acid) segment and antitumor agent comprising the same” from the University of Tokyo and TOUDAI TLO, Ltd. |
 |
| Jul |
Established Tokyo office in Chuo, Tokyo. |
 |
| Jun |
Out-licensed Paclitaxel Micelle to Nippon Kayaku Co., Ltd. |
 |
| Jan |
In-licensed “Polymeric micelle containing cisplatin enclosed therein and use thereof” from the Center for Advanced Science and Technology Incubation Ltd. (now TOUDAI TLO, Ltd.). |
 |
| Oct |
Moved head office to Tokatsu Techno Plaza in Kashiwa, Chiba, and established the lab. |
 |
| Aug |
Formed partnership with Nippon Oil & Fats Co., Ltd. (now NOF Corporation) on joint development and supply of a new block copolymer (after then, entered into a supply agreement on exclusive manufacture and supply of polymer on December 2003). |
 |
| Jun |
Founded in Setagaya, Tokyo, with the purpose of applying new block copolymers to develop pharmaceuticals and put them into practice. |
